For participants treated with local radiotherapy with or without concomitant exposure to steroids, for pain control or management of cord/nerve root compression, two weeks must have lapsed since last date of radiotherapy, which is recommended to be a limited field; participants who require concurrent radiotherapy should have entry to the protocol deferred until the radiotherapy is completed and two weeks have passed since the last date of therapy
Prior palliative radiotherapy must have been completed at least  weeks prior to study entry
Chemotherapy, radiotherapy, biologics, and/or other treatment with immunotherapy not completed four () weeks prior to first dose of study drug or without complete recovery from all such treatments.
Previous chemotherapy/radiotherapy/targeted therapy should have been completed at least  weeks prior to start of FID- administration
Prior focal radiotherapy completed at least  weeks prior to study drug administration.
Patients who have received radiation therapy within  weeks before transplant. Enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and  weeks have elapsed since the last date of therapy.
Radiation therapy within  weeks before randomization; enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and  weeks have elapsed since the last date of therapy
Chemotherapy, radiotherapy, biologics, and/or other treatment with immunotherapy not completed  weeks prior to first dose of study drug
Patients who have completed focal radiotherapy within  weeks from time of enrollment are eligible.
Patients must have completed last chemotherapy >=  weeks or radiotherapy >=  weeks prior to receiving study drugs
Prior chemotherapy, monoclonal antibody therapy, must have been completed at least  weeks prior to start. Radiotherapy or radiosurgery must have been completed at least  weeks prior to start.
Radiotherapy completed within  weeks prior to treatment initiation; radiotherapy completed >  weeks prior to treatment initiation is allowed if all procedure-related toxicities resolved
Participants in cohort D must have completed systemic therapy AND have completed either consolidation thoracic radiotherapy or PCI or both completed either consolidation thoracic radiotherapy or PCI or both; participants in cohort D must initiate therapy with pembrolizumab within  weeks of the last dose of radiation; therapy must not start within  weeks from the last dose; consolidation radiotherapy dose must NOT be more than  cGy; participants in cohort D must not have had progression of disease prior to the start of therapy
Prior radiotherapy completed < days before study enrollment.
Completed all prior therapies (immunosuppressive medications, antineoplastic therapy, vaccination, immunotherapy, chemotherapy, radiotherapy, major surgery, etc) > weeks prior to the first study dose of medication (alemtuzumab ?  months).
Prior cancer therapies not completed within  days prior to the first cycle of milataxel; radiotherapy completed less than  days prior to study enrollment; patients not recovered from radiation-related toxicities; patients receiving any concurrent anti-cancer therapy, including trastuzumab, bevacizumab or an investigational agent while on-study; patients with greater than  prior radiotherapy treatments.
Completed standard therapy ( at least  months of chemotherapy  radiotherapy )
Completed radiotherapy, chemotherapy, and/or treatment with other investigational agents at least  weeks prior to study entry
Patient has completed radiotherapy within  weeks prior to treatment initiation.
Radiation therapy within  weeks before randomization; enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and  weeks have elapsed since the last date of therapy
Patient has completed adjuvant radiotherapy (if indicated) prior to screening
Patients must have completed last chemotherapy >=  weeks or radiotherapy >=  weeks prior to receiving study drugs
Prior radiotherapy must be completed at least  weeks before patient begins study therapy.
Receiving chemotherapy, radiotherapy, biologics, and/or other antitumor treatment with immunotherapy that is not completed at least  weeks prior to study entry, unless underlying disease is progressing on therapy
Patients that have been treated with any of the following within  weeks of starting trial treatment: chemotherapy, immunotherapy, biological therapies, molecular targeted, hormone therapy (except LHRH agonists and LHRH antagonists), radiotherapy (except in case of localized radiotherapy for analgesic purpose or for lytic lesions at risk of fracture which can then be completed within  weeks prior to study treatment).
Radiation therapy within  weeks before randomization; enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and  weeks have elapsed since the last date of therapy
Participant completed all prior radiotherapy with curative intent ?  weeks prior to randomization
Radiation therapy within  days of enrollment; enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and  days have elapsed since the last date of therapy
Prior radiotherapy or radiosurgery must have been completed at least  weeks prior to start
Any radiotherapy must have been completed  weeks prior to enrollment
Chemotherapy, radiotherapy, biologics, and/or other treatment with immunotherapy not completed  weeks prior to first dose of study drug
Patients must have completed any prior radiotherapy at least  weeks prior to initiation of protocol therapy
Radiation therapy within  weeks before randomization; enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and  weeks have elapsed since the last date of therapy
Prior radiotherapy must have been completed at least  weeks prior to study entry For Arm M:
No prior treatment except for local radiation or a short course of steroids for control of symptoms; enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and  weeks have elapsed since the last date of therapy
Radiation therapy within  weeks before randomization; enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and  weeks have elapsed since the last date of therapy
Any whole brain radiotherapy (WBRT) was completed at least  weeks prior to the first dose of study drug.
Patients must have completed any previous surgery or radiotherapy >=  weeks prior to enrollment
Radiation therapy within  weeks before randomization; enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and  weeks have elapsed since the last date of therapy
Patients must have completed last chemotherapy >=  weeks or radiotherapy >=  weeks prior to receiving study drugs
Chemotherapy, radiotherapy, biologics, and/or other antitumor treatment with immunotherapy that is not completed  weeks prior to first dose of study drug.
Chemotherapy (except hydroxyurea or emergent use of single-agent cytarabine for cytoreduction), radiotherapy, biologics, and/or other treatment with immunotherapy that is not completed  weeks prior to first dose of study drug, unless progressive disease is documented; NOTE: hydroxyurea will be allowed during the first cycle of treatment
Patients treated with local radiotherapy with or without a brief ( weeks or less) exposure to steroids are eligible; patients who require concurrent radiotherapy should have entry to the protocol deferred until the radiotherapy is completed
Radiation therapy within  weeks before randomization; enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and  weeks have elapsed since the last date of therapy
Radiotherapy (RT) completed within  days prior to the first dose of study therapy.
Radiation therapy within  weeks before randomization; enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and  weeks have elapsed since the last date of therapy
No prior systemic therapy or radiation therapy active against myeloma lasting more than four weeks duration; any prior therapy must be completed a minimum of  days before starting study drugs; enrollment of subjects who require radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and  weeks have elapsed since the last date of therapy
Prior local radiotherapy is allowed if it is completed at least  weeks prior to the first dose of study drug and the subject has evaluable lesions not previously irradiated
Has completed any prior radiotherapy ?  weeks prior to randomization
Patient has completed adjuvant radiotherapy (if indicated) according to the institutional guidelines prior to screening
Prior treatment with thoracic radiotherapy completed >  weeks and =<  months prior to enrollment
Completed active treatment (surgery, chemotherapy, and/or radiotherapy) at least one month prior to study initiation (patients on continued hormone treatment will not be excluded)
No concurrent use of chemotherapy or radiotherapy (radiotherapy should be completed at least  weeks from study entry)
Must have completed radiotherapy at least  months prior to entry
Prior therapy (chemotherapy, immunotherapy, radiotherapy) must be completed at least  weeks prior to infusion of radiolabeled antibody
